Literature DB >> 35836846

miRNA-612 suppresses ovarian cancer cell tumorigenicity by downregulating NOB1.

Zhikun Shi1, Xu Zhou1, Meijing Bao1, Rongxia Jia1, Yuqing Chu1, Yang Lin1.   

Abstract

MicroRNAs (miRNAs) play crucial roles in cancer progression. Our previous study demonstrated that NIN1/RPN12 binding protein 1 homolog (NOB1) was a functional regulator in the progression of ovarian cancer (OC). However, the role of miRNA-612 (miR-612) in OC has not been elucidated. In this study, we aimed to investigate the regulatory mechanism of NOB1 targeting miRNA, miR-612, in OC tumorigenicity. The miR-612 expression was down-regulated in OC patient tissues and four OC cell lines (Caov3, A2780, SKOV3 and OVCAR3). The miR-612 level was negatively correlated with NOB1 expression, and dual-luciferase reporter assay indicated that miR-612 suppressed NOB1 expression by targeting the 3'UTR of NOB1 transcript. Up-regulation of miR-612 mediated by lentiviral transduction suppressed cell proliferation, colony formation, migration, invasion, and induced apoptosis in OC cell lines. In addition, miR-612 overexpression inhibited tumor growth of OC in vivo by sequestering NOB1 expression. In conclusion, our results suggested that miR-612 directly targeted NOB1 to suppress OC progression. Therefore, the miR-612-NOB1 axis could serve as therapeutic targets for OC. AJTR
Copyright © 2022.

Entities:  

Keywords:  NOB1; Ovarian cancer; miR-612; tumorigenicity

Year:  2022        PMID: 35836846      PMCID: PMC9274555     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  41 in total

1.  Knockdown of NOB1 expression inhibits the malignant transformation of human prostate cancer cells.

Authors:  Xiangmin Zhang; Dongxu Zhang; Fajun Qu; Yi Hong; Jianwei Cao; Xiuwu Pan; Lin Li; Yi Huang; Hai Huang; Lei Yin; Lu Chen; Jizhong Ren; Zhijun Wang; Danfeng Xu; Xingang Cui
Journal:  Mol Cell Biochem       Date:  2014-08-29       Impact factor: 3.396

Review 2.  NOB1: A Potential Biomarker or Target in Cancer.

Authors:  Weiwei Ke; Zaiming Lu; Xiangxuan Zhao
Journal:  Curr Drug Targets       Date:  2019       Impact factor: 3.465

Review 3.  MicroRNAs in cancer.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

4.  Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

Authors:  Rui-Mei Feng; Yi-Nan Zong; Su-Mei Cao; Rui-Hua Xu
Journal:  Cancer Commun (Lond)       Date:  2019-04-29

5.  MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming.

Authors:  Yang Liu; Li-Li Lu; Duo Wen; Dong-Li Liu; Li-Li Dong; Dong-Mei Gao; Xin-Yu Bian; Jian Zhou; Jia Fan; Wei-Zhong Wu
Journal:  J Hematol Oncol       Date:  2020-02-07       Impact factor: 17.388

6.  Silencing NOB1 Can Affect Cell Proliferation and Apoptosis Via the C-Jun N-Terminal Kinase Pathway in Colorectal Cancer.

Authors:  Zhong Ren; Liqing Yao; Jingzheng Liu; Zhipeng Qi; Jian Li
Journal:  J Invest Surg       Date:  2020-01-06       Impact factor: 2.533

7.  MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1).

Authors:  Jingxu Zhou; Tao Xu; Yong Yan; Rong Qin; Hongxiang Wang; Xiaoping Zhang; Yan Huang; Yuhai Wang; Yicheng Lu; Da Fu; Juxiang Chen
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

8.  Long non-coding RNA SNHG1 regulates NOB1 expression by sponging miR-326 and promotes tumorigenesis in osteosarcoma.

Authors:  Jiandong Wang; Lei Cao; Jianhong Wu; Qiugen Wang
Journal:  Int J Oncol       Date:  2017-11-03       Impact factor: 5.650

Review 9.  Circulating MicroRNAs in Cancer: Potential and Challenge.

Authors:  Mengying Cui; Hongdan Wang; Xiaoxiao Yao; Dan Zhang; Yingjun Xie; Ranji Cui; Xuewen Zhang
Journal:  Front Genet       Date:  2019-07-18       Impact factor: 4.599

Review 10.  Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.

Authors:  Chang Yang; Bai-Rong Xia; Zhao-Cong Zhang; Yong-Jian Zhang; Ge Lou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.